AARTIDRUGS / Q3-FY26 / claim-ledger

Audit the questions that mattered.

Aarti Drugs · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

WatchQ3-FY26 · 2026-02-10Back to quarter ↗

Questions audited

Answered directly

96%

Numeric claims

Consistency

contradicted

Question ledger

What was answered, and how?

Vishal · Systematics

direct

Intention of formulation business: only APIs or also other molecules?

currently we are doing both. We are working on formulations of APIs that Aarti drugs is manufacturing in house. But we are not restricting to that. Especially on our pipeline we are focusing more on niche categories into the oncology and cardiabetic range.

Vishal · Systematics

partial

Quantify savings from backward integration projects at peak utilization.

it should give a boost of say you know at least a couple of percent in gross contribution at the company level... if run at full scale potential the can be slightly upward of 50 crores

Risham Jen · BBD Asset Managers

direct

Quantify impact of shutdowns and new facilities on this quarter.

at the EBITDA level it could have created a drag of roughly 8 or 8 and a half crores and at the PBT level probably it would be around some 14 15 crores

Risham Jen · BBD Asset Managers

direct

Capex for FY27 beyond the planned 600 cr cycle.

I would still maintain that you know around 150 to 200 crores of capex you can expect for the next two years each every year

Dwani Desai · Turtle Capital

direct

Volume growth trajectory for FY27 and whether new projects drive it.

we can expect around you know 12 to 15% volume growth in FY27 with both the projects going smooth

Dwani Desai · Turtle Capital

direct

Gross margin trajectory for FY27 with backward integration.

36% gross margin is fair to assume it is not that tough to achieve 36%.

Dwani Desai · Turtle Capital

direct

Why continue capex when plants are still scaling up?

the sika plant has operationalized very smoothly... we'll know within 6 months whether one of the greenfield capex is fully operationalized or not.

Yoshi · UNIC Capital Private Limited

direct

Salicylic acid realizations and Chinese dumping status.

Chinese dumping is still on but due to dollar going up we are getting little better realization than last quarter

Yoshi · UNIC Capital Private Limited

direct

Steady-state EBITDA margins next year.

first we'll come there 12 to 13% and then from there the ideal steady state margins... should be somewhere in 14 to 15% range

Adita · Soilo Investments

direct

API pricing trajectory and whether bottom has been reached.

overall negative price variance in December quarter with respect to September 25 is roughly around 2 to 2 and a half%... we will still maintain the stance that the prices have stabilized from September onwards.

Vishal · Systematics

direct

Total investment in oncology business including dossier development.

facility capex would be about 50 crores and in terms of product development and regulatory it would be about again 50 to 60 crores every year for the next three years.

Vishal · Systematics

direct

Why choose salicylic acid as import substitute over metformin?

we studied pricing trend of salicylic acid for five to six years... that time no one was manufacturing that product and the technology showed very high profit margin... but when we entered the market China started crashing the prices.